Jade Biosciences Inc Stock Price, News & Analysis

Jade Biosciences (Nasdaq: JBIO), a biotechnology company developing therapies for autoimmune diseases, has announced its participation in two upcoming investor conferences.

CEO Tom Frohlich and CSO Dr. Andrew King will present at the H.C. Wainwright 4th Annual Kidney Virtual Conference on July 14, 2025, at 3:00 p.m. ET, and the 2025 Stifel Biotech Summer Summit on August 13, 2025, at 7:30 a.m. ET. The management team will also host one-on-one investor meetings during both events.

Jade Biosciences (NASDAQ:JBIO), a biotechnology company developing therapies for autoimmune diseases, has appointed Brad Dahms as Chief Financial Officer. Dahms brings significant experience from his previous roles as CFO and CBO at IDRx, where he orchestrated its sale to GSK for up to $1.15 billion, and as CFO of Theseus Pharmaceuticals and Selecta Biosciences.

The appointment comes as Jade prepares to advance its lead candidate JADE101 into clinical trials for IgA nephropathy this year. The company aims to leverage Dahms' expertise in financial operations, business development, and capital markets following its recent Nasdaq listing and private financing round.

Jade Biosciences (NASDAQ: JBIO) presented promising preclinical data for JADE101, its anti-APRIL monoclonal antibody for IgA nephropathy treatment, at the 62nd ERA Congress. The data revealed JADE101's superior profile with femtomolar APRIL binding affinity (50 fM), 750-fold higher than competitor sibeprenlimab. In non-human primates, JADE101 demonstrated a 27-day half-life, nearly 4x longer than sibeprenlimab, with sustained IgA suppression lasting over 100 days after a single dose. The drug showed high subcutaneous bioavailability and was designed to avoid immune complex formation risks. At just 4 mg/kg, JADE101 achieved better results than 30 mg/kg of sibeprenlimab. The company plans to initiate human trials in H2 2025, with interim data expected in H1 2026.

Jade Biosciences (NASDAQ: JBIO) announced it will present new preclinical data for JADE101, its anti-APRIL monoclonal antibody for IgA nephropathy (IgAN) treatment, at the 62nd European Renal Association Congress in Vienna (June 4-7, 2025). The presentation titled 'Discovery and Characterization of JADE101' will be delivered by Erin Filbert, Executive Director of Research and Translational Medicine, during the Focused Oral Session on June 6, 2025. The company will host a conference call and webcast on June 9, 2025, at 8:00 a.m. ET to discuss the presented data, with registration available on the company's website.

Jade Biosciences (NASDAQ: JBIO) reported its Q1 2025 financial results and corporate updates. The company completed a reverse merger with Aerovate Therapeutics and commenced trading on Nasdaq, raising approximately $300 million to date. Key highlights include:

The company's lead candidate JADE101, an anti-APRIL monoclonal antibody for IgAN, is expected to begin first-in-human trials in H2 2025, with interim data expected in H1 2026. Additionally, Jade nominated JADE201 as a development candidate from their JADE-002 program.

Financial results show cash and equivalents of $49.9 million as of March 31, 2025, with an additional $205 million gross proceeds from the April merger. Q1 2025 saw R&D expenses of $20.0 million, G&A expenses of $3.4 million, and a net loss of $38.2 million. The company expects its current cash position to provide runway through 2027.

Jade Biosciences (NASDAQ: JBIO), a biotechnology company specializing in autoimmune disease therapies, has announced its participation in the upcoming Jefferies Global Healthcare Conference from June 3-5, 2025, in New York. CEO Tom Frohlich will deliver a company presentation on June 4 at 4:55-5:25 p.m. ET. The management team will also conduct investor meetings during the event.

The presentation will be accessible to investors and the public through the Investors and Media section of JadeBiosciences.com, with the recording remaining available for 90 days afterward.